Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.15 USD | -3.08% | -16.89% | +35.78% |
Mar. 20 | North American Morning Briefing : Markets on Hold -2- | DJ |
Mar. 19 | JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5 | MT |
Financials (USD)
Sales 2024 * | 39.05M | Sales 2025 * | 33.24M | Capitalization | 382M |
---|---|---|---|---|---|
Net income 2024 * | -83M | Net income 2025 * | -97M | EV / Sales 2024 * | 6.96 x |
Net cash position 2024 * | 110M | Net cash position 2025 * | 23.7M | EV / Sales 2025 * | 10.8 x |
P/E ratio 2024 * |
-4.75
x | P/E ratio 2025 * |
-4.36
x | Employees | 123 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.32% |
Latest transcript on Mersana Therapeutics, Inc.
1 day | -3.08% | ||
1 week | -16.89% | ||
Current month | -29.69% | ||
1 month | -32.98% | ||
3 months | +11.70% | ||
6 months | +107.24% | ||
Current year | +35.78% |
Managers | Title | Age | Since |
---|---|---|---|
Martin Huber
CEO | Chief Executive Officer | 64 | 20-04-12 |
Director of Finance/CFO | 46 | 19-07-09 | |
David Mott
CHM | Chairman | 58 | 12-07-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kristen Hege
BRD | Director/Board Member | 60 | 16-07-31 |
David Mott
CHM | Chairman | 58 | 12-07-30 |
Anna Protopapas
BRD | Director/Board Member | 59 | 15-03-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - | |
0.03% | 237 M€ | -0.44% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-22 | 3.15 | -3.08% | 1,803,183 |
24-04-19 | 3.25 | -2.69% | 2,390,380 |
24-04-18 | 3.34 | -5.11% | 1,273,917 |
24-04-17 | 3.52 | -6.38% | 2,603,879 |
24-04-16 | 3.76 | -0.79% | 683,041 |
Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.78% | 382M | |
+2.49% | 96.73B | |
-0.23% | 21.31B | |
-16.61% | 21.21B | |
-5.01% | 18.79B | |
-42.14% | 16.37B | |
-27.40% | 13.68B | |
+1.44% | 13.44B | |
+21.29% | 10.98B | |
-21.79% | 8.56B |
- Stock Market
- Equities
- MRSN Stock